You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. LAUR-201 (V-Smart®-TNV for Neuro-HIV): Novel V-Smart® Nanomedicine for Treatment of HAND

    SBC: LAUREN SCIENCES LLC            Topic: 105

    Lauren Sciences goal is to advance development of its innovative V-Smart® Nanomedicine for Neuro-HIV, LAUR- 201 (V-Smart®-Tenofovir for Neuro-HIV), as a disease-modifying therapeutic for the critical unmet medical needs of 50% of the 40 million HIV patients worldwide who, despite suppressive antiretroviral therapy (ART), suffer from HIV-associated neurocognitive disorders (HAND). Currently, ther ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic Vaccine for Asthma

    SBC: MERCIA PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Asthma is a chronic lung disease affecting some 150 million people worldwide. An estimated 20.3 million Americans have asthma, of which 6.3 million are children. The current therapeutic approaches for the treatment of asthma, whose prevalence and mortality are increasing, have had limited impact on clinical management and resolution of the disorder. The eotax ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Jigsawdio: an AudioVisual Jigsaw Puzzle for People with Alzheimer's Disease and Alzheimer's-Disease-Related Dementias

    SBC: CALLAHAN-YOUNG LLC            Topic: NIA

    Social isolation leads to loneliness, which is linked to depression, stress, high blood pressure, and poor sleep, all of which accelerate cognitive decline. The prolonged social isolation that resulted from the COVID-19 pandemic has further highlighted the importance of social connection. Developing new strategies to support AD/ADRD patients and their families is a public health priority, particul ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Single Agent Antibiofilm Antibiotics

    SBC: Synoxa Sciences, Inc            Topic: NIAID

    Project Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial agents based on the marine natural product lipoxazolidinone A to treat recalcitrant Gram-positive infections. These scaffo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Antigen Capture Assay for Babesia microti

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections

    SBC: Synoxa Sciences, Inc            Topic: NIAID

    Project Summary Natural products have served as a productive source of drugs over the past decades and have represented, or been the inspiration for, a majority of antimicrobial compounds that have entered the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A software tool for objective identification of concussion-related vision disorders using a novel eye-tracking device

    SBC: Oculogica Inc.            Topic: 102

    ABSTRACT This project will create the first objective measurement toolthe VisBoxfor the vision subtype of concussionVSCThis will enable physicians to identify VSC without an eye care professionalfor referral to a vision specialist for personalized vision therapy recommendationsThe persistence of concussion symptoms beyond several weeks is often a life altering situation for affected individualsand ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government